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What is the key question?   
Do longitudinal wheezing patterns during early childhood indicate differences in long-term 
prognosis of respiratory illnesses? 
 
What is the bottom line?  
Early onset wheezing phenotypes persisting after 18 months of age showed the strongest 
associations with adverse respiratory outcomes in adolescence. 
 
Why read on?  
The current study suggests evidence for associations of specific wheezing phenotypes 
during early childhood with asthma, low lung function and increased allergic airway 
inflammation in adolescence, and additionally, lung function worsening from mid-childhood 
until adolescence.  
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ABSTRACT 
  
Background Longitudinal wheezing patterns during early childhood may indicate differences 
in long-term prognosis of respiratory illnesses. We examined the associations of different 
childhood wheezing phenotypes with asthma, lung function and fractional exhaled nitric 
oxide (FeNO) in adolescence. 
Methods In a population-based, prospective cohort study of 6,841 children, we used latent 
class analysis to identify wheezing phenotypes (never/infrequent; transient early; prolonged 
early; intermediate-onset; late-onset; persistent) from birth to 7 years. Main outcomes were 
assessed at age 14-15 years and included information about physician-diagnosed asthma, 
lung function (forced expiratory volume in 1 s (FEV1), ratio FEV1/forced vital capacity (FVC), 
forced mid-expiratory flow (FEF25-75), and FeNO. 
Results Compared with never/infrequent wheeze, intermediate-onset and persistent wheeze 
were consistently strongest associated with higher odds of asthma (odds ratio [95% CI]: 52.7 
[31.4, 88.2]; 38.9 [29.1, 51.9], respectively), lower FEV1/FVC ratio (mean difference standard 
deviation-units [MD-SDU] [95% CI]: -0.36 [-0.56, -0.16]; -0.50 [-0.62, -0.38], respectively), 
lower FEF25-75 (MD-SDU: -0.30 [-0.51, -0.10]; -0.42 [-0.54, -0.29], respectively), and 
increased FEV1 bronchodilator reversibility (MD-SDU: 0.11 [0.01, 0.22]; 0.18 [0.06, 0.30], 
respectively) at age 14-15 years. Prolonged early and persistent wheeze were associated 
with a decline in FEV1/FVC ratio and FEF25-75 between 8-9 and 14-15 years. Intermediate-
onset, late-onset and persistent wheeze were associated with higher FeNO ratios (ratio 
[95% CI]: 1.93 [1.59, 2.34]; 1.60 [1.42, 1.81]; 1.37 [1.22, 1.54], respectively, compared with 
never/infrequent wheeze).  
Conclusions Early onset wheezing phenotypes persisting after 18 months of age show the 
strongest associations with asthma, lower lung function and higher FeNO levels in 
adolescence. 
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INTRODUCTION   
Asthma is a complex heterogeneous disease comprising a number of discrete phenotypes. 
Childhood wheezing is the most common clinical manifestation of asthma onset. Severe and 
persistent childhood wheezing patterns are more likely to lead to asthma and abnormal 
pulmonary function in later life, than mild and transient childhood wheezing patterns (1-4). 
Recently, a novel symptom-driven approach to define different wheezing patterns was 
introduced using repeated measurements of wheeze during the first 7 years of childhood in a 
large population-based birth cohort study, the Avon Longitudinal Study of Parents and 
Children (ALSPAC) (5). This led to the identification of six different phenotypes including 
never/infrequent wheezing, transient early wheezing, prolonged early wheezing, 
intermediate-onset wheezing, late-onset wheezing, and persistent wheezing. We found that 
intermediate-onset wheezing showed the strongest associations with atopy, airway 
hyperresponssiveness and lower lung function in mid-childhood. Thus far, it is not known 
whether the higher risk of asthma and abnormal pulmonary function in mid-childhood 
persists or worsen into adolescence, or whether different wheezing phenotypes in early 
childhood are related to eosinophilic airway inflammation, which can be assessed using the 
fractional concentration of nitric oxide in exhaled air (FeNO).  
Therefore, we examined the associations of previously reported wheezing phenotypes 
during the first 7 years of childhood with asthma, lung function and FeNO in adolescence in 
the ALSPAC birth cohort study. We also examined whether any associations were modified 
by tobacco smoke exposure during pregnancy or early childhood, active smoking and 
reported use of asthma medications. 
 
METHODS  
Design and setting This study was embedded in ALSPAC, a population-based birth cohort 
study of pregnant women resident in Avon, UK, and their children (6). The cohort has been 
followed up with annual questionnaires and, since the age of 7 years, with objective 
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measures in research clinics. The study protocol has been published previously (6) and 
further details can be found at http://www.bris.ac.uk/alspac. 
Wheezing phenotypes At 6, 18, 30, 42, 54, 69 and 81 months after birth, mothers were 
sent a self-completion questionnaire about the health of their child. In 2 separate sections, 
they reported the occurrence of wheezing in the previous 12 months (6 months for the initial 
questionnaire) and, if present, whether they consulted a physician. Wheeze was defined as 
present if the response to any of the questions about wheezing was ‘‘yes’’ and absent if the 
response to both was ‘‘no’’. All other combinations were classified as missing (1.3%).  
Asthma Information on asthma was obtained by a parent-completed questionnaire at a 
mean age of 14 (SD 0.16) years. Parents reported whether a physician ever diagnosed 
asthma or eczema in their child (no; yes, asthma; yes, eczema; yes, asthma and eczema) or 
whether their child had asthma during the past 12 months (no; yes, did not see a physician; 
yes, did see a physician). Based on the first obtained question, we grouped children into 
‘ever physician-diagnosed asthma’ (no; yes, asthma or asthma and eczema). Reported 
asthma during the past 12 months was used to reclassify ‘ever physician-diagnosed asthma’ 
(no; yes) where appropriate.  
Lung function Children visited research clinics at mean ages of 8.6 (SD 0.25) and 15.4 (SD 
0.30) years. Lung function was measured by spirometry (Vitalograph 2120, Maids Moreton, 
UK) according to American Thoracic Society criteria (7). Each variable (forced expiratory 
volume in 1 s (FEV1), forced vital capacity (FVC) and mid forced expiratory flow (FEF25–75)) 
was converted into sex-, age- and height-adjusted standard deviation units (SDU) (8). 
Bronchodilator reversibility was calculated as the difference in SDU of lung function variables 
change before and 15 minutes after receiving 400 micrograms of salbutamol by metered 
aerosol and spacer. Lung function change between mid-childhood and adolescence was 
calculated as the difference in SDU of lung function variables between these two 
assessments.  
FeNO Fractional exhaled nitric oxide (FeNO) was measured online at a constant flow of 
50mL/s according to European Respiratory Society (ERS) and American Thoracic Society 
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(ATS) guidelines using a Sievers NOA-280i nitric oxide analyser (GE Analytical Instruments, 
Boulder, CO.). Additionally, 758 children with less stringent criteria (individual blows >5% 
deviation but at least 1 within acceptable rang of 10-200 ppb) were included. FeNO 
measurements were done before spirometry measurements. Children were requested to 
omit their inhaled corticosteroids if applicable 48 hours before their visit to the clinic. At the 
time of measurements, 14 children (0.3%) received oral steroids, 221 (5.2%) had a chest 
infection and/or fever with a cold in the preceding three weeks, and 39 (0.9%) and 89 (2.1%) 
had used short acting or long acting bronchodilators 6 or 24 hours, respectively, prior to the 
respiratory assessments. These children, and those with less stringent criteria of FeNO 
values, were included in our analyses since we observed no differences in results when they 
were included or excluded. 
Covariates Information on maternal age, deprivation index, anxiety, smoking during 
pregnancy and history of asthma or allergy were obtained from self-completion 
questionnaires at 18 weeks or 32 weeks of gestation. Birth weight, gestational age and 
gender of the children were obtained from midwife and hospital registries at birth. Childhood 
maternal questionnaires from 3-15 months after birth provided information about 
breastfeeding, home overcrowding (>0.75 persons per room), pet contact and childhood 
smoke exposure. At 14 years of age, parents reported if their child had a chest infection in 
the past 12 months, ever had hay fever or eczema, and use of medication for asthma (no; 
yes, preventer inhaler; yes, reliever inhaler; yes, other inhaler or asthma medicine). Children 
themselves reported if they actively smoked (yes: sometimes but < 1 a week; usually 1-6 a 
week; usually > 6 a week but not every day, usually ≥ 1 every day) or not (no; only ever tried 
once or twice; used sometimes but never now). 
Statistical analysis We used latent class analysis to derive distinct phenotypes of wheezing 
as described previously (5). Briefly, this identifies the minimum number of classes that 
describe the variation of observed responses in multicategorical data which in this case were 
wheeze at different time points (9). The posterior probabilities (probability of each individual 
of belonging to each phenotype) were estimated and used in weighted logistic and linear 
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regression models to estimate associations of wheezing phenotypes with physician-
diagnosed asthma, lung function and FeNO levels in adolescence. Similar analyses were 
used with bronchodilator reversibility and longitudinal lung function change between mid-
childhood and adolescence as continuous outcome variables. Confounders were included in 
the adjusted models based on literature or change in effect estimates of ≥ 10%. We 
additionally adjusted for lung function data in mid-childhood when lung function changes 
between mid-childhood and adolescence were used as the outcomes. Data on confounders 
was missing for 7% at most and included in the analyses as separate categories or means. 
We explored effect modification of exposure to smoke during pregnancy or early life, active 
smoking of the child and use of asthma medication by including these variables as 
interaction terms in the linear regression models with lung function and FeNO as the 
outcomes. Finally, to assess whether the associations of the wheezing phenotypes with 
FeNO levels were modified by the use of inhaled corticosteroids, we repeated these 
analyses with FeNO levels as the outcome in strata of reported inhaled corticosteroid use 
(no, yes). FeNO levels were log-transformed to obtain normality and therefore geometric 
means and ratios of geometric means are reported. Measures of associations with FeNO 
levels as the outcome are presented as back-transformed geometric means or ratios. All 
measures of association are presented with their 95% confidence intervals (CI). Statistical 
analyses were performed using Stata v11 (StataCorp, College Station, TX). 
 
RESULTS 
Wheezing phenotypes were characterized by timing of onset and subsequent decline or 
persistence: never/infrequent wheeze (no or low frequency wheeze < 6 months; 61%), 
transient early wheeze (6-18 months; 13%), prolonged early wheeze (6-69 months; 10%), 
intermediate-onset wheeze (>18 months; 2%), late-onset wheeze (>42 months; 6%), and 
persistent wheeze (>6 months; 8%) (5).  Of 11.678 children with information about wheezing 
phenotypes during the first 7 years of life, 6,841 (59%) had data on at least one respiratory 
outcome. Characteristics of the study population are shown in table 1.  
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Wheezing phenotypes, asthma and lung function All wheezing phenotypes were 
associated with asthma at age 15 (Supplementary Table S1). The strongest associations for 
asthma were observed for the intermediate-onset (odds ratio [OR] [95% confidence interval]: 
52.7 [31.4, 88.2]) and persistent wheeze phenotype (OR 38.9 [29.1, 51.9]), compared with 
never/infrequent wheeze. 
Compared with never/infrequent wheeze in early childhood, only persistent wheeze was 
associated with lower levels of FEV1 (mean difference in standard deviation unit [SDU] [95% 
confidence interval]: -0.15 [-0.27, -0.02]) at age 15 years (Figure 1A, Supplementary Table 
S2). Wheezing phenotypes were associated with lower FEV1/FVC and, except for transient 
early wheeze, with lower FEF25-75 (Figures 1B and C, respectively, Supplementary Table 
S2). Compared with never/infrequent wheeze, all wheezing phenotypes, except transient 
early wheeze, showed evidence of increased bronchodilator reversibility of FEV1 and FEF25-
75  but not consistently for FEV1/FVC (Figures 1A-C, Supplementary Table S2). Prolonged 
early and persistent wheeze were most consistently associated with a decline in change of 
FEV1/FVC ratio (Mean difference in SDU [95%CI]: -0.25 [-0.36, -0.15] and -0.28 [-0.40, -
0.15], respectively) and change of FEF25-75  (-0.10 [-0.20, -0.00] and -0.14 [-0.25, -0.02], 
respectively) between 8-9 and 14-15 years (Figure 2B and C, Supplementary Table S3). We 
found no strong evidence for modification lung function by prenatal smoke exposure, 
childhood smoke exposure, active smoking or use of asthma medication (results not 
reported, p-values for interaction > 0.05). 
Wheezing phenotypes and FeNO Compared with never/infrequent wheeze, intermediate-
onset, late-onset and persistent wheeze, were associated with higher ratios of FeNO at age 
14-15 years (Ratio of geometric means [95% CI]: 1.93 [1.59, 2.34], 1.60 [1.42, 1.81], and 
1.37 [1.22, 1.54], respectively) (Figure 3, Supplementary Table S4). Higher odds for FeNO 
were observed for these wheezing phenotypes when we used the clinical cut-off level of high 
FeNO of ≥ 20 ppb (OR 2.31 [1.18, 4.54], 2.03 [1.36, 3.05] and 1.45 [1.01, 2.08], respectively) 
(Supplementary Table S5). Among children diagnosed with asthma, use of a corticosteroid 
inhaler was associated with higher levels of FeNO compared with those children who did not 
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use a corticosteroid inhaler (54.3 ppb vs 26.6 ppb, p-value <0.01). Stratified analyses 
showed that the associations of intermediate-onset, late-onset and persistent wheeze with 
levels of FeNO were stronger in children who did not use a corticosteroid inhaler, but the 
evidence for an interaction was weak (Supplementary Table S6; p-value for interaction > 
0.05). Similarly, there was no strong evidence that the associations of wheezing phenotypes 
with levels of FeNO were modified by smoke exposure during pregnancy, childhood smoke 
exposure, or active smoking (results not reported, p-values for interaction > 0.05). 
 
DISCUSSION 
Our results suggest that previously observed associations of wheezing phenotypes during 
the first 7 years of life with increased odds of asthma and lower lung function in mid-
childhood persist until adolescence. Additionally, we observed that prolonged early and 
persistent wheeze were associated with a further decline in lung function between the ages 
of 8-9 and 14-15 years. Also, we found evidence for increased allergic airway inflammation 
at 14-15 years for the intermediate-onset, late-onset and persistent wheezing phenotypes.  
 
Interpretation of findings We previously identified two unreported wheezing phenotypes 
during the first 7 years of childhood including prolonged early and intermediate-onset 
wheezing (10). The intermediate-onset wheezing phenotype was replicated (11) and 
validated (12) in two independent birth cohorts and, additionally, evidence was provided that 
latent class analysis derived wheezing phenotypes are clinically distinct and have different 
genetic origins (13, 14). We now show that the associations of intermediate-onset, late-onset 
and persistent wheezing phenotypes with asthma in adolescence are consistent with both 
our previously published associations with outcomes at younger ages (5, 11), and other 
studies using different categories of wheezing and asthma in late childhood and 
adolescence (3, 15). Among currently wheezing children aged 10 years, asthma was 
diagnosed more often for persistent than late-onset wheezing children (76.0% vs. 51.9%, 
p<0.01) (15). Also, late-onset and persistent, and not transient early, wheezing children were 
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more likely to continue to wheeze from age 8-9 to 14-15 years (OR 3.12 [2.5, 3.9] and 3.8 
[3.1, 4.7], respectively), compared with children who never wheezed (3).  
Previous studies reported inconsistent results for the associations of wheezing phenotypes 
with pulmonary function in adolescence (3, 15-17). The differences in results might be 
explained by the different study designs, small number of subjects for sufficient power to 
detect small effects, definition of wheezing, time point, and method of lung function, such as 
spirometry, multiple-breath wash-out or peak flow variability, measured. Of studies that 
observed associations between wheezing phenotypes and lung function measured by 
spirometry, the strongest and most consistent effects were observed for persistent wheezing 
with lower levels of FEV1 (-87 ml to -90 ml) and FEV1/FVC ratio (-2.5% to -3.4%), compared 
with the never wheezing phenotype (3, 15), even into adulthood (2). Our results suggest that 
the two recently identified wheezing phenotypes, prolonged early and intermediate-onset, 
are also negatively associated with lung function into adolescence. Possible mechanisms of 
lower lung function in adolescence include developmental abnormalities persisting from 
infancy, and ongoing inflammation and repair of the airways leading to remodeling. This is 
supported by the evidence of increased airway inflammation levels in adolescence for our 
intermediate-onset, late-onset, and persistent wheezing phenotypes.  
We observed associations of prolonged early and persistent wheezing with change in lung 
function between 8-9 years and 14-15 years, which implies that irreversible adverse changes 
persist and for some wheezing phenotypes further decline after early childhood. Our results 
are partly consistent with findings from the Tuscon study that showed associations of early 
transient wheeze with lower maximal expiratory flow at the ages of 2.4 months and 6, 11 and 
16 years (3). Late-onset wheeze was not associated with maximal expiratory flow at any 
age, but persistent wheeze was associated with maximal expiratory flow at 6 years and 
older. However, they did not observe a further decline of lung function after the age of 6 
years for the phenotypes when compared with their peers.  
Our results with levels of FeNO as a respiratory morbidity outcome are not in line with 
previous studies, which did not show higher levels of FeNO due to a specific wheezing 
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phenotype (17-20). Differences with our results could be explained by their use of other 
definitions of wheezing phenotype (multi-trigger vs. episodic, atopic vs. non-atopic, recurrent 
vs. no wheezing phenotype), partly lack of adjustment for confounders, younger age at 
which FeNO levels were measured, and smaller sample sized cohorts. Our observed effect 
estimates of the associations between wheezing phenotypes and FeNO were consistently 
strongest for intermediate-onset wheeze when mean levels of FeNO, ratios of continuously 
measured FeNO or clinical cut-off levels of FeNO were used. This might be due to different 
specific underlying mechanisms for specific wheezing phenotypes. We speculate that the 
intermediate-onset and late-onset wheezing phenotype mostly arise due to atopic 
mechanisms including sensitivity to common allergens (5, 21) leading to higher risk of 
(atopic) asthma, higher levels of FeNO and lower lung function, while persistent wheezing 
phenotype arise due to a mixture of growth, infectious and atopic mechanisms (22-25) 
leading to lower lung function only. FeNO levels were low compared with clinic-based 
samples. However, in the current population-based sample, which probably contains a 
higher proportion of mild asthmatics, there was still clear evidence of wheezing phenotype 
associated airway inflammation. 
 
Strengths and methodological issues This study was embedded in a population-based, 
prospective cohort study with a large number of subjects being studied from early life 
onwards with detailed and frequently measured information about wheezing, asthma and 
lung function, and adjustment for a large number of confounders. Furthermore, this cohort 
study is the first study that measured levels of FeNO in adolescence. In common with most 
longitudinal cohort studies, there was loss to follow up that was not random. Of children with 
complete cases on wheezing until age 7 years (n = 6,265) (5), the range of missing values 
on respiratory assessments at age 15 years was 8.3% (asthma) to 55.8% (FeNO). Selection 
bias due to loss to follow-up would be present in our study if the associations of wheezing 
phenotypes with respiratory outcomes were different between adolescents lost to follow-up 
and those who remained in the study. Although this cannot be totally excluded, qualitative 
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conclusions about the direction and approximate magnitude of the effect estimates will most 
probably not change (26). We used parental-reported wheezing symptoms which is widely 
accepted in epidemiological studies (27). Under- or overreporting could be present but 
misclassification of wheeze influencing our results seem unlikely because seven 
observations were used, and latent class analyses allows for misclassification. However, 
data on treatment with inhaled steroids was not available < 8 years of age and 
misclassification due to suppression of symptoms by treatment might be present. The 
wheeze patterns that were observed in our data were not constrained by prespecified 
notions of their number or nature. The strong associations of the wheezing phenotypes with 
asthma, lung function, and levels of FeNO until adolescence confirms the appropriate use of 
wheeze patterns derived by latent class analyses at least in population-based cohorts 
studying underlying mechanisms and prognosis of respiratory morbidity. Other phenotypes 
such as episodic viral and multi-trigger wheeze seem more appropriate for clinical practice 
(28).  Whether all different classifications of wheeze identified for various purposes 
eventually merge remains to be studied. Although we adjusted for a large number of 
confounders, residual confounding due to obesity (29) or genetic variants (30-32) might be 
present. 
 
In conclusion, our study suggest that associations of wheezing patterns in early childhood 
with increased odds of asthma and lower lung function in mid childhood persist until 
adolescence. Lung function from mid childhood until adolescence further declined for the 
prolonged early and persistent wheezing phenotypes. We found evidence for increased 
allergic airway inflammation in adolescence for wheezing phenotypes with early onset that 
persisted after 18 months of age. Further studies are needed to explore possible underlying 
mechanisms to develop specific intervention strategies that optimize lung development in 
early life and prevent additional decline by adolescence. 
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Table 1. Characteristics of children and their mothers.  
Values are absolute numbers (percentages), means (SD) or #medians (5-95th percentile). 
 
 
 
Cohort for analysis 
n = 6,841 
  
 N measured (%) 
Mean (SD) or  
median (5-95
th
 percentile) 
Mother   
Age at delivery (years) 6,841 (100) 29.1 (4.6) 
Maternal deprivation index
#
 6,669 (97.5) 12.6 (4.9-43.2) 
Parity ≥ 1 6,660 (97.4) 3,485 (52.3) 
Anxiety index at 32 weeks gestation
#
 6,351 (92.8) 4.0 (0-12) 
Smoking during pregnancy (%) 6,623 (96.8) 1,278 (19.3) 
History of asthma or allergy (%) 6,571 (96.1) 3,094 (47.1) 
   
Child   
Gender (female) 6,841 (100) 3,425 (50.1) 
Preterm birth (<37 weeks) (%) 6,841 (100) 331 (4.8) 
Low birth weight (<2.5 kg) (%) 6,764 (98.9) 279 (4.1) 
Ever breastfed in first 6 months (%) 6,553 (95.8) 5,344 (81.6) 
Overcrowded at home (%) 6,592 (96.4) 1,248 (18.9) 
Day care attendance during 1
st
 year (%) 6,525 (95.4) 439 (6.7)  
Pet contact during 1
st
 year (%) 6,574 (96.1) 4,513 (68.6) 
Childhood smoke exposure 1
st
 year  (%) 6,518 (95.3) 1,180 (18.1) 
Age at respiratory assessments (years) 4,798 (70.1) 15.4 (0.3) 
Height (cm), age 15 y 4,750 (69.4) 169.3 (8.3) 
Active smoking, age 14-15 y (%) 5,902 (86.3) 1,375 (23.3) 
Asthma treatment, age 14 y (%)   
 ‘Preventer’ inhaler 4,952 (72.4) 414 (8.4) 
 ‘Reliever’ inhaler 5,096 (74.5) 594 (11.7) 
 Other inhaler or asthma medicine 4,646 (67.9) 58 (1.3)  
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Figure 1. Association of wheezing phenotypes with lung function in 14-15 year old 
adolescents. 
Values are mean differences of sex-, age- and height-adjusted standard deviation units of 
primary (●) and bronchodilator reversibility (○) lung function measurements with their 95% 
confidence intervals (95% CI), compared with never/infrequent wheeze. FEV1, forced 
expiratory volume in 1 second (A); FEV1/FVC, forced expiratory volume in 1 second / forced 
vital capacity (B); FEF25–75, mid forced expiratory flow (C). Models are adjusted for maternal 
age at delivery, parity, anxiety, smoking during pregnancy, history of asthma and allergy, 
children’s sex, low birth weight, preterm birth, breastfeeding and childhood tobacco smoke 
exposure.  
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Figure 2. Association of wheezing phenotypes with lung function change between mid-
childhood (8-9 years) and adolescence (14-15 years). 
Values are mean differences of sex-, age- and height-adjusted standard deviation units with 
their 95% confidence intervals (95% CI), compared with never/infrequent wheeze. FEV1, 
forced expiratory volume in 1 second (A); FEV1/FVC, forced expiratory volume in 1 second / 
forced vital capacity (B); FEF25–75, mid forced expiratory flow (C). Models are adjusted for 
maternal age at delivery, parity, anxiety, smoking during pregnancy, history of asthma and 
allergy, children’s sex, low birth weight, preterm birth, breastfeeding and childhood tobacco 
smoke exposure, and additionally for lung function standard deviations scores in mid-
childhood. 
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Figure 3. Association of wheezing phenotypes with Fractional exhaled Nitric Oxide (FeNO) 
in 14-15 year old adolescents. 
Values are ratios of geometric means (●) with their 95% confidence interval (95% CI), 
compared with never/infrequent wheeze, and geometric means (∆). Models are adjusted for 
maternal age at delivery, parity, anxiety, smoking during pregnancy, history of asthma and 
allergy, children’s sex, low birth weight, preterm birth, breastfeeding and childhood tobacco 
smoke exposure. 
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Table S1. Association of wheezing phenotypes with physician-diagnosed asthma in 14-15 
year old adolescents. 
Values are odds ratios (OR) with their 95% confidence Interval (95% CI), compared with 
never/infrequent wheeze. Models are adjusted for maternal age at delivery, parity, anxiety, 
smoking during pregnancy, history of asthma and allergy, children’s sex, low birth weight, 
preterm birth, breastfeeding and childhood tobacco smoke exposure.
 
Ever physician-diagnosed asthma at 14-15 years 
 
n = 5,742 
 
n/total (%) OR (95% CI) 
Wheezing phenotype 
  
Never/infrequent 
458/3,589 (12.8) (1.00 (reference) 
Transient early 
151/701 (21.6) 1.88 (1.55, 2.30) 
Prolonged early 
191/527 (36.3) 3.89 (3.17, 4.76) 
Intermediate-onset 
131/148 (88.5) 52.65 (31.44, 88.18) 
Late-onset  
232/365 (63.6) 11.91 (9.41, 15.06) 
Persistent 
350/412 (85.0) 38.88 (29.11, 51.91) 
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Table S2 (Figure 1). Association of wheezing phenotypes with lung function in 14-15 year old adolescents. 
Values are mean differences of sex-, age- and height-adjusted standard deviation units of primary (A) and bronchodilator reversibility (B) lung 
function measurements with their 95% confidence intervals (95% CI), compared with never/infrequent wheeze. FEV1, forced expiratory volume 
in 1 second; FEV1/FVC, forced expiratory volume in 1 second / forced vital capacity; FEF25–75, mid forced expiratory flow. Models are adjusted 
for maternal age at delivery, parity, anxiety, smoking during pregnancy, history of asthma and allergy, children’s sex, low birth weight, preterm 
birth, breastfeeding and childhood tobacco smoke exposure.  
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 Lung function (SDU) at 14-15 years 
 FEV1   FEV1/FVC   FEF25-75   
 n = 4,072   n = 4,072   n= 4,145   
 
Total Mean (SD) 
Mean difference 
(95%CI) 
Total Mean (SD) 
Mean difference 
(95%CI) 
Total Mean (SD) 
Mean difference 
(95%CI) 
Phenotype          
Never/infrequent 2,567 0.02 (1.00) 0 (reference) 2,567 0.10 (0.93) 0 (reference) 2,617 0.08 (0.99) 0 (reference)  
Transient early 500 0.02 (1.01) -0.01 (-0.10, 0.09) 500 -0.01 (0.99) -0.11 (-0.20, -0.01) 509 0.02 (0.99) -0.07 (-0.17, 0.02) 
Prolonged early 373 -0.09 (0.99) -0.11 (-0.22, 0.01) 373 -0.24 (1.09) -0.34 (-0.45, -0.23) 377 -0.19 (0.99) -0.28 (-0.38, -0.17) 
Intermediate-onset 96 -0.11 (0.95) -0.14 (-0.34, 0.07) 96 -0.25 (1.22) -0.36 (-0.56, -0.16) 97 -0.22 (1.09) -0.30 (-0.51, -0.10) 
Late-onset  261 -0.10 (1.03) -0.12 (-0.25, 0.01) 261 -0.12 (1.00) -0.22 (-0.34, -0.09) 264 -0.15 (0.97) -0.24 (-0.36, -0.11) 
Persistent 275 -0.12 (1.05) -0.15 (-0.27, -0.02) 275 -0.40 (1.24) -0.5 (-0.62, -0.38) 281 -0.33 (1.04) -0.42 (-0.54, -0.29) 
 Bronchodilator reversibility (SDU) at 14-15 years 
 FEV1   FEV1/FVC   FEF25-75   
 n = 3,540   n = 3,540   n= 3,701   
 Total Mean (SD) 
Mean difference 
(95%CI) 
Total Mean (SD) 
Mean difference 
(95%CI) 
Total Mean (SD) 
Mean difference 
(95%CI) 
Never/infrequent 2,225 -0.04 (0.46) 0 (reference)  2,225 -0.02 (0.71) 0 (reference) 2,345 -0.04 (0.57) 0 (reference) 
Transient early 443 -0.03 (0.52) 0.02 (-0.03, 0.07) 443 -0.01 (0.88) 0.01 (-0.06, 0.09) 456 -0.05 (0.54) -0.01 (-0.07, 0.04) 
Prolonged early 322 0.02 (0.45) 0.06 (0.01, 0.12) 322 0.07 (0.76) 0.09 (0.01, 0.18) 331 0.03 (0.52) 0.06 (0, 0.13) 
Intermediate-onset 83 0.07 (0.57) 0.11 (0.01, 0.22) 83 0.10 (0.59) 0.13 (-0.04, 0.29) 86 0.14 (0.53) 0.18 (0.06, 0.3) 
Late-onset  227 0.06 (0.48) 0.10 (0.04, 0.17) 227 0.06 (0.70) 0.08 (-0.02, 0.18) 235 0.10 (0.56) 0.14 (0.06, 0.21) 
Persistent 240 0.08 (0.47) 0.13 (0.06, 0.19) 240 0.15 (0.66) 0.18 (0.08, 0.28) 248 0.10 (0.51) 0.14 (0.06, 0.20) 
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Table S3 (Figure 2). Association of wheezing phenotypes with lung function change between mid-childhood (8-9 years) and adolescence (14-
15 years). 
Values are mean differences of sex-, age- and height-adjusted adjusted standard deviation units with their 95% confidence intervals (95% CI), 
compared with never/infrequent wheeze. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF25–75, mid forced 
expiratory flow; SD, standard deviation; SDU, standard deviation unit. Models are adjusted for maternal age at delivery, parity, anxiety, smoking 
during pregnancy, history of asthma and allergy, children’s sex, low birth weight, preterm birth, breastfeeding and childhood tobacco smoke 
exposure, and additionally for lung function standard deviations scores in mid-childhood.
 
Change in lung function (SDU) from 8 - 15 years 
 FEV1 FEV1/FVC FEF25-75 
 n = 3,471 n = 3,392 n = 3,573 
 
Total Mean (SD) 
Mean difference 
(95%CI) 
Total Mean (SD) 
Mean difference 
(95%CI) 
Total  Mean (SD) 
Mean difference 
(95%CI) 
Phenotype          
Never/infrequent 2,189 -0.02 (1.07) 0 (reference) 2,138 -0.02 (1.00) 0 (reference) 2,257 -0.04 (0.99) 0 (reference) 
Transient early 428 0.09 (1.07) 0.03 (-0.06, 0.13) 418 0.01 (1.01) -0.06 (-0.15, 0.03) 441 0.06 (0.93) 0.01 (-0.07, 0.10) 
Prolonged early 321 0.10 (1.05) -0.02 (-0.13, 0.08) 314 -0.07 (1.14) -0.25 (-0.36, -0.15) 326 0.05 (0.92) -0.10 (-0.20, -0.00) 
Intermediate-onset 82 0.16 (1.25) 0.00 (-0.20, 0.20) 79 0.26 (1.43) -0.10 (-0.20, 0.10) 84 0.28 (1.13) 0.04 (-0.15, 0.23) 
Late-onset  218 0.01 (1.13) -0.06 (-0.18, 0.07) 214 0.03 (1.12) -0.12 (-0.25, -0.01) 223 0.03 (0.99) -0.08 (-0.20, 0.04) 
Persistent 233 0.12 (1.11) -0.01 (-0.13, 0.11) 229 0.02 (1.21) -0.28 (-0.40, -0.15) 242 0.07 (0.92) -0.14 (-0.25, -0.02) 
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Table S4 (Figure 3) Association of wheezing phenotypes with Fractional exhaled Nitric 
Oxide (FeNO) in 14-15 year old adolescents. 
Values are ratios with their 95% confidence interval (95% CI), compared with 
never/infrequent wheeze, and geometric means. Models are adjusted for maternal age at 
delivery, parity, anxiety, smoking during pregnancy, history of asthma and allergy, children’s 
sex, low birth weight, preterm birth, breastfeeding and childhood tobacco smoke exposure. 
 
 FeNO at 14-15 years 
 n = 2,767 
 
Total 
Geometric
mean (SD) 
Ratio of geometric 
mean  (95%CI) 
Phenotype    
Never/infrequent 1.781 26.1 (1.97) 1.00 (reference) 
Transient early 342 26.3 (1.99) 0.96 (0.88, 1.05) 
Prolonged early 248 26.8 (2.16) 0.94 (0.85, 1.04) 
Intermediate-onset 62 54.6 (2.61) 1.93 (1.59, 2.34) 
Late-onset  156 43.4 (2.53) 1.60 (1.42, 1.81) 
Persistent 178 37.0 (2.34) 1.37 (1.22, 1.54) 
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Table S5. Association of wheezing phenotypes with clinical cut-off (≥ 20 ppb) of Fractional 
exhaled Nitric Oxide in 14-15 year old adolescents. 
Values are odds ratios with their 95% confidence intervals (95% CI), compared with 
never/infrequent wheeze. Models are adjusted for maternal age at delivery, parity, anxiety, 
smoking during pregnancy, history of asthma and allergy, children’s sex, low birth weight, 
preterm birth, breastfeeding and childhood tobacco smoke exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FeNO ≥ 20 ppb at 14-15 years 
 n = 2,767 
 
n/total (%) OR (95%) 
Phenotype   
Never/infrequent 1,053/1,781 (59.1) 1.00 (reference) 
Transient early 204/342 (59.6) 0.97 (0.75, 0.25) 
Prolonged early 143/248 (57.7) 0.86 (0.64, 1.16) 
Intermediate-onset 47/62 (75.8) 2.31 (1.18, 4.51) 
Late-onset  116/156 (74.3) 2.03 (1.36, 3.05) 
Persistent 119/178 (66.9) 1.45 (1.01, 2.08) 
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Table S6. Association of wheezing phenotypes with Fractional exhaled Nitric Oxide and the 
use of inhaled corticosteroids in 14-15 year old adolescents. 
Values are ratios of geometric means with their 95% confidence intervals (95% CI), 
compared with never/infrequent wheeze. Models are adjusted for maternal age at delivery, 
parity, anxiety, smoking during pregnancy, history of asthma and allergy, children’s sex, low 
birth weight, preterm birth, breastfeeding and childhood tobacco smoke exposure. *Missing 
data on use of inhaled corticosteroid (ICS) (n = 820). 
 
 
 
  
FeNO at 14-15 years 
Ratio of geometric means (95% CI) 
  Total group  Non - ICS use*  ICS use* 
  n = 2,767 n = 1,810 n = 137 
Phenotype     
Never/infrequent 1,782 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Transient early 342 0.96 (0.88, 1.05) 0.98 (0.88, 1.08) 0.73 (0.35, 1.53) 
Prolonged early 247 0.94 (0.85, 1.04) 0.97 (0.86, 1.09) 0.47 (0.23, 0.93) 
Intermediate-onset 61 1.93 (1.59, 2.34) 1.63 (1.24, 2.15) 1.38 (0.74, 2.57) 
Late-onset  156 1.60 (1.42, 1.81) 1.52 (1.31, 1.78) 1.10 (0.60, 2.00) 
Persistent 177 1.37 (1.22, 1.54) 1.19 (1.02, 1.39) 0.91 (0.53, 1.55) 
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